CN119095602A - 增强的dna树枝状聚合物及其使用方法 - Google Patents

增强的dna树枝状聚合物及其使用方法 Download PDF

Info

Publication number
CN119095602A
CN119095602A CN202380021051.XA CN202380021051A CN119095602A CN 119095602 A CN119095602 A CN 119095602A CN 202380021051 A CN202380021051 A CN 202380021051A CN 119095602 A CN119095602 A CN 119095602A
Authority
CN
China
Prior art keywords
composition
polynucleotide
cargo
molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380021051.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·C·盖茨
J·M·卢克
S·Z·布朗
C·J·马塞纳
L·A·盖茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Code Biotherapy Co
Original Assignee
Code Biotherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Biotherapy Co filed Critical Code Biotherapy Co
Publication of CN119095602A publication Critical patent/CN119095602A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202380021051.XA 2022-02-10 2023-02-09 增强的dna树枝状聚合物及其使用方法 Pending CN119095602A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308776P 2022-02-10 2022-02-10
US63/308,776 2022-02-10
PCT/US2023/062270 WO2023154788A2 (en) 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof

Publications (1)

Publication Number Publication Date
CN119095602A true CN119095602A (zh) 2024-12-06

Family

ID=87565106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380021051.XA Pending CN119095602A (zh) 2022-02-10 2023-02-09 增强的dna树枝状聚合物及其使用方法

Country Status (8)

Country Link
US (1) US20230338557A1 (https=)
EP (1) EP4475891A2 (https=)
JP (1) JP2025507359A (https=)
CN (1) CN119095602A (https=)
AU (1) AU2023217717A1 (https=)
CA (1) CA3243817A1 (https=)
IL (1) IL314724A (https=)
WO (1) WO2023154788A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them
WO2025034978A1 (en) * 2023-08-09 2025-02-13 Code Biotherapeutics, Inc. Enhanced dna dendrimers and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950825B1 (en) * 2013-02-01 2019-09-11 Genisphere, LLC Functionalized dna dendrimers for gene delivery to cells
CN109844134B (zh) * 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
KR20220133999A (ko) * 2020-01-31 2022-10-05 타이리스 테라뷰틱스, 에스.엘. 변형된 뉴클레오티드들을 갖는 닫힌 선형 dna
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them

Also Published As

Publication number Publication date
AU2023217717A1 (en) 2024-08-29
EP4475891A2 (en) 2024-12-18
IL314724A (en) 2024-10-01
JP2025507359A (ja) 2025-03-18
CA3243817A1 (en) 2023-08-17
WO2023154788A3 (en) 2023-11-09
WO2023154788A2 (en) 2023-08-17
US20230338557A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20260048118A1 (en) Compositions and methods for enhancing triplex and nuclease-based gene editing
US11779653B2 (en) Multi-armed polyrotaxane platform for protected nucleic acid delivery
KR102873209B1 (ko) 조건부 활성 폴리펩티드 및 이를 제조하는 방법
CN111770757A (zh) 诱导外显子跳读的核酸-多肽组合物和方法
CA3111518A1 (en) Compositions and methods for enhancing donor oligonucleotide-based gene editing
CN111225975A (zh) 抗体介导的cas9向哺乳动物细胞的递送
JP2025528052A (ja) 脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法
JP2023537798A (ja) 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
US20230338557A1 (en) Enhanced dna dendrimers and methods of use thereof
US12338436B2 (en) Synthetic guide molecules, compositions and methods relating thereto
WO2024073042A1 (en) Ocular delivery of therapeutic agents
KR20240040112A (ko) 방법
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
KR20260047657A (ko) Pln 표적화 항체-올리고뉴클레오티드 접합체의 조성물 및 사용 방법
CN113507942A (zh) 分子的细胞内靶向
JP6795492B2 (ja) ＣＬＣＮ７（ＡＤＯ２ ＣＬＣＮ７依存性）遺伝子変異によって引き起こされる常染色体優性大理石骨病２型（ＡＤＯ２）療法のための短鎖干渉ＲＮＡ（ｓｉＲＮＡ）
WO2025034978A1 (en) Enhanced dna dendrimers and methods of use thereof
US12139713B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
US20260125688A1 (en) Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
JP2025537167A (ja) カルシウム電位開口型チャネル補助サブユニットガンマ１（ｃａｃｎｇ１）結合タンパク質及び骨格筋へのｃａｃｎｇ１媒介送達
JP2025538220A (ja) アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
WO2025038901A1 (en) Cyclic peptides for delivering therapeutics
WO2025122871A1 (en) Multi-armed dendrimeric oligonucleotide nanoarchitectures to target the cyclic gmp-amp (cgas)/cyclic gmp-amp receptor stimulator of interferon genes (sting) pathway
WO2026090491A1 (en) Enhanced delivery of disease-targeted nanobody-sirna conjugates
AU2024325879A1 (en) Intracellular targeting of oligonucleotides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination